Colorectal cancer (CRC) continues to pose a significant challenge due to its ability to bypass the immune system. Specifically, recent findings highlight the role of the ZNF30/B4GALT2/MUC20 axis in CRC immune evasion. Researchers discovered that CRC cells overexpress the zinc finger protein ZNF30. This protein then triggers the expression of the glycosyltransferase B4GALT2. Consequently, this pathway allows the cancer to progress by manipulating the surrounding immune environment.

The process involves B4GALT2, which modifies the protein MUC20 through N-glycosylation. Furthermore, this glycosylated MUC20 interacts with Siglec-7 receptors on the surface of macrophages. This interaction is critical because it induces M2 polarization. Unlike M1 macrophages, M2 macrophages suppress active immune responses. Therefore, the tumor effectively creates a protective shield against T-cell attacks.

Targeting the ZNF30 Axis to Combat CRC Immune Evasion

Additionally, in vivo experiments have confirmed that this regulatory axis promotes tumor growth and metastasis. Notably, identifying MUC20's aberrant glycosylation provides a fresh perspective on cancer treatment. This discovery offers new predictive markers for advanced CRC patients. Moreover, it presents therapeutic targets that could potentially reverse the immunosuppressive state of the tumor microenvironment. Because early detection is vital, these markers may significantly improve clinical outcomes for those with advanced disease.

Frequently Asked Questions

What is the role of MUC20 in colorectal cancer?

MUC20 undergoes abnormal glycosylation in CRC cells. Once modified, it interacts with Siglec-7 on macrophages to promote an immunosuppressive environment that aids tumor survival.

How does the ZNF30 protein influence CRC progression?

ZNF30 acts as a transcriptional activator for B4GALT2. This activation leads to the glycosylation of MUC20, which ultimately drives macrophage polarization and tumor metastasis.

Can these findings lead to new CRC treatments?

Yes. The study highlights the ZNF30/B4GALT2/MUC20 axis as a potential therapeutic target. Inhibiting this pathway could disrupt the immune evasion mechanism and enhance the body's anti-tumor response.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.

References

Zhi Y et al. Abnormal glycosylation of MUC20 mediates TAM polarization and promotes immune escape in colorectal cancer. Commun Biol. 2026 Apr 11. doi: 10.1038/s42003-026-10017-1. PMID: 41965932.

Vitale C et al. Role of Siglec-7 and Siglec-9 in regulating immune cell function in cancer. Front Immunol. 2019;10:1991.

Crocker PR et al. Siglecs and their roles in immune regulation. Nat Rev Immunol. 2007;7(4):255-266.